Idiopathic Pulmonary Fibrosis
Conditions
Keywords
omeprazole, idiopathic pulmonary fibrosis
Brief summary
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause in which areas of normal lung tissue are replaced by scars. As a result it becomes harder for the lungs to extract oxygen from the air. IPF is commonly progressive, and around 50% of patients diagnosed with the disease die after approximately 3 years. The most common, troublesome symptoms of IPF are breathlessness on exertion, and cough. No drug treatments have been unequivocally shown to improve the death rate, or to significantly impact upon symptoms, in IPF. In recent years it has been recognised that cough can be caused by small amounts of liquid coming up from the stomach and going down the wrong way into the lungs, a process commonly known as reflux. As liquid in the stomach is usually acidic, patients' lungs may repeatedly be exposed to small amounts of acid. Reflux is unusually common in IPF and could potentially contribute to the debilitating cough found with the disease. However there are many potential causes for cough in IPF. Stomach acid can be efficiently switched off by drugs called proton pump inhibitors, one of which is called omeprazole. If reflux of stomach acid does contribute to cough in IPF, omeprazole might be expected to reduce cough. The purpose of this study is therefore to test whether omeprazole does reduce cough in patients with IPF. Sixty patients with IPF will be randomly allocated to have 3 months of omeprazole or a placebo. Neither the patient nor the doctor will be aware which treatment has been given, ie this is a randomised double-blind, placebo--controlled trial. Patients' cough frequency will be measured before and after treatment and the change in cough frequency compared in those receiving omeprazole and those receiving placebo. Change in cough frequency is the main thing we aim to compare, but a range of other measurements will be assessed such as the numbers of patients eligible to take part, agreeing to randomisation and providing outcome data, patients' lung function, symptom scores, the amount of reflux, and the amount of inflammation in the lungs.
Interventions
DRUGOmeprazole
Drug
DRUGMatched placebo
Matched placebo
Sponsors
Newcastle University
Newcastle-upon-Tyne Hospitals NHS Trust
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* IPF is considered the most likely diagnosis by the Regional Interstitial Lung Disease Multidisciplinary Team meeting (ILD-MDT). * History of cough, with or without exertional dyspnoea. * High resolution computed tomography (HRCT) scan features of honeycombing in a predominantly basal subpleural distribution. * Bibasal crackles on auscultation. * Features of a restrictive ventilatory defect \[vital capacity (VC) \<90% predicted and/or diffusion factor for carbon monoxide (Tco) \<90% predicted\]. * Aged 40-85 years. * Patients taking short courses (eg. 2 months) of proton pump inhibitors (PPI) will be eligible once the treatment has been discontinued for a minimum of 1 month.
Exclusion criteria
* Known allergy to Omeprazole or other proton pump inhibitor. * Concomitant use of warfarin, diazepam, phenytoin, ketoconazole. * Concomitant use of a regular PPI, antacid, prokinetic or raft alginate during the trial period. * History of upper respiratory tract infection, lower respiratory tract infection or exacerbation of IPF in the 4 weeks before starting study drugs. * Active trial of treatment for IPF 9eg. prednisolone, pirfenidone, N-acetylcysteine) started in the 4 weeks before starting study drugs. * Documented history of hepatic cirrhosis. * Pregnancy or lactation. * ILD-MDT considers the most likely cause of he patient's ILD to be a condition other than IPF (eg. rheumatoid lung, systemic sclerosis ILD, asbestosis, chronic hypersensitivity pneumonitis, sarcoidosis, etc.). * Concurrent enrolment in a trial of a Clinical Trial of Investigational Medicinal Product (CTIMP) for IPF.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| objectively measured cough frequency | 90 days | the change in frequency of objectively measured cough from beginning of the study to the end of treatment (within 2 weeks of completion of treatment). This will be compared in the two groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| vital capacity (VC) & transfer factor for carbon monoxide (Tco) | 90 days | change in VC and Tco as measured by lung function tests |
| 6 minute walk distance | 90 days | change in 6 minute walk distance from baseline to 90 days |
| symptoms of cough | 90 days | change in symptoms of cough at the end of treatment as measured by validated cough questionnaire |
| reflux symptoms | 90 days | change in symptoms of reflux as measured by validated questionnaires |
| lung infection rate | 90 days | assess bronchoalveolar lavage (BAL) fluid for infections over period from baseline to 90 days, also patient reported infection in adverse event diary |
| adverse events rate | 90 days | patient reported adverse events, assess lung infection rate in bronchoalveolar fluids over period from baseline to 90 days |
| acid and non-acid reflux | 90 days | change in acid and non-acid reflux measured by oesophageal physiological study |
| assess amount of inflammation in lung | 90 days | assess markers of lung inflammation in bronchoalveolar lavage (BAL) fluid (eg. concentration of transforming growth factor beta, interleukin-8 etc.) |
Other
| Measure | Time frame | Description |
|---|---|---|
| rate of recruitment | 18 months | Number of participants eligible and consented for study |
| rate of study completion | 18 months | Number of participants completing all study procedures (over 90 days for each participant) |
Countries
United Kingdom
Outcome results
None listed